These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 18435868

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
    Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
    Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E.
    Arch Gynecol Obstet; 2009 Jun 21; 279(6):803-7. PubMed ID: 18936950
    [Abstract] [Full Text] [Related]

  • 8. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.
    J Infect Dis; 2009 Apr 01; 199(7):926-35. PubMed ID: 19236279
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and incidence of HPV genital infection in women.
    Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A.
    Sex Transm Dis; 2009 Nov 01; 36(11):696-703. PubMed ID: 19652630
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug 01; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

  • 13. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL.
    Int J Infect Dis; 2007 Nov 01; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
    Lehtinen M, Idänpään-Heikkilä I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, Liljamo T, Luostarinen T, Apter D, Pukkala E, Paavonen J.
    Int J STD AIDS; 2006 Apr 01; 17(4):237-46. PubMed ID: 16595046
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
    Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Reisinger KS, Protocol 016 Study Group.
    Pediatrics; 2006 Nov 01; 118(5):2135-45. PubMed ID: 17079588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.